A low attenuation lesion in the liver is an area that appears darker than the surrounding liver tissue on a CT scan, meaning it absorbs fewer X-rays than normal liver parenchyma. The term describes a radiological appearance, not a specific diagnosis. Most of these lesions turn out to be benign, with simple cysts and hemangiomas being the most frequent culprits, but the same dark appearance on a scan can also represent infections, fatty deposits that mimic masses, or malignant tumors. Understanding what your radiologist means by “low attenuation” and what the next steps look like can take a lot of the anxiety out of an otherwise unsettling report.
Why Something Shows Up as “Low Attenuation”
On a CT scan, different tissues absorb X-rays to different degrees. Denser structures like bone absorb a lot and appear bright (high attenuation), while tissues with more water, fat, or air absorb less and appear dark (low attenuation). Normal liver tissue typically measures somewhere around 50 to 65 Hounsfield units (HU) on an unenhanced scan. Anything registering well below that range stands out as a darker spot. When researchers have developed automated tools to measure liver density, they use cutoffs like 40 HU to flag abnormally low attenuation, such as in the detection of fatty liver disease.1PubMed Central. Fully automatic liver attenuation estimation combing CNN segmentation and morphological operations
A lesion can appear dark because it is filled with fluid (like a cyst), because it contains fat, because it has poor blood supply compared to the rest of the liver, or because it is composed of tissue that is simply less dense. The key diagnostic challenge is figuring out which of these explanations applies, because the clinical significance ranges from completely harmless to urgently requiring treatment.
Simple Cysts
The single most common cause of a low attenuation lesion in the liver is a simple hepatic cyst. These are fluid-filled sacs lined by a thin layer of cells, and they occur in a sizable fraction of the adult population. On CT, they appear as sharply defined, round or oval dark spots that measure close to water density (around 0 to 20 HU). They do not enhance with contrast dye, meaning they stay dark through every phase of a contrast-enhanced scan. That behavior is a strong reassuring signal.
Simple cysts are almost always incidental findings. They rarely cause symptoms unless they grow large enough to press on surrounding structures. A radiologist diagnosing a simple cyst based on CT or ultrasound criteria will typically recommend no follow-up at all. Where things get more complex is when a cystic lesion has internal walls, thick septa, or solid-looking components, because those features push the differential toward less common possibilities like biliary hamartomas, cystadenomas, or parasitic cysts. In those situations, additional imaging or closer surveillance becomes appropriate.2American Journal of Roentgenology (AJR). Cystic hepatic lesions: a review and an algorithmic approach
Hemangiomas
Hemangiomas are the most common solid benign liver tumor and another frequent source of low attenuation findings. These are tangles of blood-filled vascular spaces, and on an unenhanced CT scan they often appear as a well-defined dark area. What makes them distinctive is how they behave when contrast dye is injected. In a classic hemangioma, the dye fills in from the edges inward in a pattern radiologists call “peripheral nodular enhancement.” This progressive fill-in can take minutes, and on delayed imaging the lesion often becomes uniformly bright or nearly so.
In one study of hemangioma enhancement patterns on spiral CT, the most common pattern was peripheral nodular high attenuation during both the arterial and portal venous phases, seen in about 56% of cases. The second most common was uniform high enhancement, at roughly 13%.3PubMed. Hepatic hemangioma: contrast-enhancement pattern during the arterial and portal venous phases of spiral CT That classic fill-in pattern is so recognizable that many hemangiomas can be confidently diagnosed on CT alone without further workup.
Small hemangiomas, however, can be tricky. Those under 2 cm sometimes show atypical patterns, including remaining low attenuation even after contrast, which can mimic other lesions.3PubMed. Hepatic hemangioma: contrast-enhancement pattern during the arterial and portal venous phases of spiral CT When a multiphase CT study directly compared hemangioma enhancement to blood pool structures like the aorta and hepatic veins, most hemangiomas showed statistically different attenuation from those vessels, meaning they don’t perfectly track with blood pool, which can make borderline cases harder to call.4PubMed. Contrast enhancement of hepatic hemangiomas on multiphase MDCT: Can we diagnose hepatic hemangiomas by comparing enhancement with blood pool? In those ambiguous situations, MRI usually resolves the question.
Focal Nodular Hyperplasia and Hepatic Adenomas
Two other benign solid lesions can present as low or near-normal attenuation masses on an unenhanced CT scan: focal nodular hyperplasia (FNH) and hepatic adenoma. Both are most commonly found in women of reproductive age. On an unenhanced scan, they tend to measure close to normal liver density, so they can be subtle or even invisible without contrast. One study found that FNH averaged about 51 HU and adenomas about 56 HU before contrast, a difference too small to reliably distinguish them on an unenhanced scan alone.5PubMed. Focal nodular hyperplasia and hepatocellular adenoma of the liver: differentiation with multiphasic helical CT
The difference becomes more apparent once contrast arrives. FNH is a highly vascular lesion and lights up intensely during the arterial phase, averaging around 118 HU in that same study, compared to about 80 HU for adenomas. By the portal venous phase, the two look similar again at roughly 110 to 112 HU. So the arterial phase is where radiologists get the most useful information for telling them apart.5PubMed. Focal nodular hyperplasia and hepatocellular adenoma of the liver: differentiation with multiphasic helical CT FNH also sometimes shows a characteristic central fibrous scar with arterial vessels running through it, a finding that strongly favors the diagnosis.6PubMed. Hepatic adenomas and focal nodular hyperplasia: dynamic CT study
This distinction matters clinically. FNH is considered essentially a benign curiosity that rarely requires treatment. Hepatic adenomas, by contrast, carry a small risk of hemorrhage and, in certain subtypes, malignant transformation, so they are managed more actively, sometimes with surgical removal.
Liver Abscesses
Infections can produce low attenuation lesions that look quite different from tumors but still need to be distinguished from them. A liver abscess, whether caused by bacteria, amoebae, or fungi, typically appears as a thick-walled area of low attenuation, sometimes with surrounding edema that creates a “double target” sign on CT.7European Society of Radiology. Infectious Lesions of the Liver – Spectrum of Imaging Findings
Amebic liver abscesses, the most common type worldwide, show interesting morphological variation. Research categorizing these abscesses on CT found three distinct types. The majority, about two-thirds, had ragged edges with absent or incomplete walls and irregular enhancement. Roughly a quarter had a complete wall with rim enhancement and a surrounding low-density halo. A small minority showed a wall without any enhancement at all.8PubMed Central. Hepatobiliary CT of amebic liver abscess: different morphological types with different clinical features The clinical picture, including fever, travel history, and blood work, usually helps point toward an abscess rather than a tumor, but the imaging overlap can be genuine, especially when the abscess has an atypical appearance.
Hepatocellular Carcinoma and the Washout Pattern
When the conversation turns to malignant low attenuation liver lesions, hepatocellular carcinoma (HCC) is the most important one to discuss. HCC is the most common primary liver cancer and usually develops in the setting of chronic liver disease or cirrhosis. Its imaging behavior on multiphase CT is distinctive enough that many cases can be diagnosed without a biopsy.
The hallmark is a two-part pattern: the lesion enhances brightly during the arterial phase (because HCC draws its blood supply from the hepatic artery), then becomes darker than the surrounding liver on the portal venous or delayed phase. That second part, where the lesion fades while the background liver holds onto contrast, is called “washout.” It is considered an excellent predictor of HCC.9PubMed. Quantitatively defining washout in hepatocellular carcinoma Research into why washout occurs has shown that it relates to the extracellular volume fraction of the tumor compared to the surrounding liver tissue.10PubMed Central. What is the “washout” of hepatocellular carcinoma as observed on the equilibrium phase CT?: consideration based on the concept of extracellular volume fraction
A person without known liver disease who has a low attenuation lesion found incidentally is far less likely to have HCC. But in someone with cirrhosis, hepatitis B, or other chronic liver conditions, even a small low attenuation nodule triggers a specific diagnostic algorithm involving multiphase imaging. Early detection in this population is one of the main goals of liver surveillance programs.
Cholangiocarcinoma and Delayed Enhancement
Cholangiocarcinoma, a cancer arising from the bile ducts within or adjacent to the liver, behaves very differently from HCC on imaging. On initial scans, it often appears as a low-density or isodense mass, sometimes barely visible. Unlike HCC, which enhances early and washes out, cholangiocarcinoma tends to show delayed contrast enhancement, meaning it actually gets brighter on scans taken minutes after contrast injection.11PubMed. Cholangiocarcinoma: delayed CT contrast enhancement patterns
This delayed enhancement happens because cholangiocarcinoma contains a lot of fibrous tissue, which slowly absorbs and retains contrast. In studies of hilar cholangiocarcinoma specifically, lesions that appeared low-density on unenhanced and early dynamic CT scans were seen as high-density masses on scans taken 8 to 15 minutes later.12PubMed. CT of hilar cholangiocarcinoma: late contrast enhancement in six patients This pattern is essentially the opposite of HCC’s behavior, and recognizing it is an important part of distinguishing between the two.
Focal Fatty Infiltration and Other Look-Alikes
Not every dark spot on a liver CT is a true lesion. One of the most common mimics is focal fatty infiltration, where fat deposits accumulate in a localized patch of liver tissue rather than diffusely throughout the organ. On CT, these fatty patches appear as geometric or ovoid areas of low attenuation, typically in characteristic locations near the falciform ligament, gallbladder fossa, or porta hepatis.13PubMed. Focal fatty infiltration of the liver: analysis of prevalence and CT findings in children and young adults
What sets focal fatty infiltration apart from a real mass is that blood vessels run through it normally without being displaced or distorted. The patch also has no mass effect on surrounding structures. In cases where the CT appearance is ambiguous, MRI with fat-sensitive sequences can confirm the diagnosis within seconds, because fat produces a very specific signal drop on opposed-phase imaging. Recognizing this pseudolesion prevents unnecessary biopsies and worry.
Other non-neoplastic mimics include areas of altered blood flow near the liver’s venous drainage, perfusion defects, and post-treatment changes in patients who have had prior liver procedures. Radiologists keep these possibilities in mind, especially when a low attenuation area has an unusual shape or location that doesn’t fit a typical mass pattern.
How Doctors Sort Through the Possibilities
The imaging approach to characterizing low attenuation liver lesions relies heavily on multiphase contrast-enhanced CT. Instead of taking a single snapshot, the scanner captures images at several time points after contrast injection: the arterial phase (when blood is flowing through arteries), the portal venous phase (when contrast reaches the liver through the portal vein), and often a delayed phase. Each lesion type has a different enhancement “fingerprint” across these phases. Techniques using multirow detector CT scanners have been developed specifically to separate these distinct hepatic circulatory phases and optimize detection of hypervascular tumors.14PubMed. Multiphase hepatic CT with a multirow detector CT scanner
When CT alone cannot provide a confident answer, MRI is the next step and is widely considered the gold standard for characterizing liver lesions. Contrast-enhanced MRI using a liver-specific contrast agent called gadoxetic acid adds an extra dimension to the evaluation. Unlike standard contrast agents, gadoxetic acid is taken up by functioning liver cells, producing what is called a “hepatobiliary phase” of imaging. Normal liver tissue brightens on this phase, while most malignant lesions and certain benign ones do not, creating a clear contrast.15PubMed Central. Indeterminate liver lesions on gadoxetic acid-enhanced magnetic resonance imaging of the liver: Case-based radiologic-pathologic review
Gadoxetic acid-enhanced MRI is particularly useful for distinguishing between FNH and hepatic adenoma (since FNH takes up the agent and adenoma does not), for identifying early HCC, and for preoperative assessment of liver metastases.16PubMed Central. Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI Lesions that show low signal intensity on the hepatobiliary phase without typical vascular features carry a higher probability of being malignant, a finding that can push the clinical team toward biopsy or closer follow-up.
When Low Attenuation Lesions Turn Up in Cancer Patients
A particularly anxiety-provoking scenario is when a low attenuation liver lesion is found in someone who already has a known cancer elsewhere in the body. Modern CT scanners are sensitive enough to pick up tiny lesions that would have gone unnoticed a generation ago, and many of those incidental findings turn out to be benign cysts or hemangiomas even in oncology patients. Distinguishing between a harmless cyst and a tiny metastasis carries enormous stakes, because the answer can change whether a patient is considered to have localized or metastatic disease, with all the treatment implications that follow.17PubMed Central. That liver lesion on MDCT in the oncology patient: is it important?
Lesions that are too small to characterize on CT, often called “too small to characterize” or TSTC in radiology reports, represent a real management challenge. They may be as small as a few millimeters and simply do not have enough volume for the scanner to reliably determine their composition. In these cases, follow-up imaging at an interval, MRI, or contrast-enhanced ultrasound may be used to resolve the ambiguity. The decision depends on the type and stage of the primary cancer, the size and number of indeterminate lesions, and the patient’s overall clinical picture.
Low Attenuation Lesions in Children
The differential diagnosis shifts when a low attenuation liver lesion is found in a child. Benign tumors account for a larger share of pediatric liver masses compared to adults. Congenital hepatic hemangiomas are among the most common, and the imaging workup needs to consider possibilities that are rare in adults, like mesenchymal hamartoma, which appears as a multiseptated cystic lesion, or hepatoblastoma, the most common malignant liver tumor of early childhood. Biochemical markers like alpha-fetoprotein levels become important in the pediatric setting, since elevated levels point toward hepatoblastoma rather than a benign vascular lesion.18South African Journal of Radiology. Benign paediatric liver tumours: The radiological maze demystified
Because children are more sensitive to radiation, imaging strategies also differ. Ultrasound and MRI are preferred over CT when possible, and the threshold for repeated CT scanning is higher. A pediatric radiologist familiar with the specific spectrum of liver lesions in children is an important part of the diagnostic team.
Automated Detection and the Future of Characterization
Researchers are actively developing machine learning tools that can analyze the texture and density patterns within liver lesions on unenhanced CT scans and predict whether they are benign or malignant. One recent approach used automated machine learning algorithms to extract hundreds of quantitative features from CT images and combine them with clinical data. The resulting fusion model showed strong performance in distinguishing benign from malignant lesions without requiring contrast injection.19PubMed Central. Radiomics-based automated machine learning for differentiating focal liver lesions on unenhanced computed tomography
These tools are not replacing radiologists, but they represent a promising direction, especially for triaging incidental findings or for patients who cannot receive intravenous contrast due to kidney problems or allergies. If the technology matures, it could reduce the number of follow-up scans and invasive procedures needed to reach a diagnosis, which would be a meaningful improvement in how we handle the vast number of low attenuation liver lesions discovered each year on imaging done for other reasons.